Zoldonrasib Enters First-Line NSCLC Phase 3, but RVMD Thesis Unchanged

What happened

On October 20, 2026, Revolution Medicines announced it has begun treating patients in RASolve 308, a global Phase 3 trial evaluating its G12D-selective inhibitor zoldonrasib in combination with pembrolizumab and chemotherapy for first-line metastatic non-squamous NSCLC harboring RAS G12D mutations. This marks the company's first registrational trial in the first-line NSCLC setting, expanding zoldonrasib beyond its previously planned first-line PDAC studies and later-line NSCLC work. The move aligns with management's stated strategy to capture earlier-line, larger patient populations and build a multi-asset RAS(ON) franchise. However, the DeepValue master report had already flagged zoldonrasib's first-line NSCLC program as a key near-term catalyst, and this announcement is merely the formal start of dosing rather than a data readout. Consequently, while the news confirms execution, it does not provide new efficacy or safety information that would alter the fundamental investment case for RVMD at its current valuation near $98 per share.

Implication

Investors should maintain a cautious stance: the zoldonrasib first-line NSCLC program is still years away from potential approval, and while it expands the addressable market, the company continues to burn over $1 billion annually with no approved products. The stock's premium valuation embeds success across multiple pivotal trials, and this news does nothing to de-risk the binary outcomes. Until randomized data from RASolute 302 or other late-stage trials emerges, the risk/reward appears unfavorable, suggesting trimming or avoiding new positions and reassessing after a pullback or clearer efficacy signals.

Thesis delta

The core thesis remains that RVMD is overvalued relative to its near-term catalysts and high cash burn. Today's announcement confirms pipeline progression but is an incremental milestone, not a value-changing event. No adjustment to the 'potential sell' rating or conviction is warranted.